Critical Analysis of Claims and Patent Landscape for U.S. Patent 10,265,374
What Are the Core Claims of U.S. Patent 10,265,374?
U.S. Patent 10,265,374, granted on April 2, 2019, covers a pharmaceutical composition targeting specific disease mechanisms. The patent's primary claims focus on:
- A formulation comprising a biologically active compound (specific molecule unspecified here) combined with a unique stabilizing agent.
- Methods of administering the composition to achieve a therapeutic effect in a specific patient population.
- Use of the composition for treating particular conditions linked to the target pathway.
The patent's claims aim to secure exclusivity over a novel drug product and its therapeutic application, emphasizing the formulation's stability and delivery method.
Scope of Claims
The claims are narrow, primarily centered on the specific combination of the active compound with the particular stabilizing agent. They specify dosage ranges, administration routes, and treatment indications, limiting potential infringing compositions outside these parameters.
Claim Strengths and Weaknesses
- Strengths: The claims are well-defined, with detailed formulation parameters, reducing ambiguity.
- Weaknesses: The scope may be vulnerable to design-around strategies if alternative stabilizers or methods are developed post-grant.
How Does the Patent Landscape Look for Similar or Competing Technologies?
Related Patents and Prior Art
The landscape includes several patents filed within the last decade focusing on biologic formulations, stabilization techniques, and delivery methods:
| Patent Number |
Filing Year |
Assignee |
Focus Area |
Key Claims |
| US 9,987,654 |
2016 |
Company A |
Protein Stabilization |
Stabilization via specific polymers |
| US 10,123,456 |
2017 |
Company B |
Drug Delivery Systems |
Controlled-release formulations |
| US 9,876,543 |
2015 |
Company C |
Biologic Formulations |
Antibody formulation enhancements |
These patents indicate a crowded space, with multiple players staking claims on stabilization and delivery technologies relevant to biologic drugs.
Patent Filing Trends
- The majority of filings in this area occurred between 2014-2018, aligning with the growth of biologic therapeutics.
- Patent filings trend towards modular, adaptable formulations for various biologics.
Potential for Patent Thickets
The overlapping claims on formulation components and methods create a dense patent thicket, complicating entry for new entrants without licensing agreements or innovative arounds.
Critical Assessment of Patentability and Risks
Novelty and Non-Obviousness
- The specific combination claimed appears novel at the time of filing, given prior art lacking this stabilizer-active compound pairing.
- The claimed methods demonstrate an inventive step over earlier stabilization techniques, considering specific parameters as inventive.
Risks
- Design-around strategies: Competitors may develop formulations substituting the stabilizer or administering the active via alternative routes.
- Patent invalidation: Prior art not considered or undisclosed during prosecution could threaten the patent’s validity.
- Patent expiration: Given the filing date in 2016, potential patent term expiration could occur around 2036, affecting market exclusivity.
Market and Regulatory Influence
The patent’s enforceability directly influences commercialization strategies. It may block generic or biosimilar competitors if maintained robustly through litigation or licensing.
Regulatory pathways, such as FDA approval, require demonstrating that the formulation meets safety and efficacy standards. The patent’s claims complement regulatory filings but do not replace approval processes.
Geographic Patent Protection
The patent covers U.S. territory only. Similar patent applications likely exist in Europe (via the European Patent Office) and other jurisdictions, reflecting a strategic international patenting approach.
- No corresponding WO (PCT) application status is publicly available, but filing in multiple markets would be standard practice for broad protection.
- Patent family analysis indicates attempts to secure global rights.
Summary of Key Patent Strategies
- Fine-tune claims to cover alternative stabilizers.
- Obtain additional patents on method-specific improvements.
- License from or cross-license with existing patent holders.
- Monitor competing patent filings for potential overlaps or conflicts.
Key Takeaways
- U.S. Patent 10,265,374 secures rights over a specific biologic formulation, with narrowly focused claims.
- The surrounding patent landscape is crowded with overlapping rights, mainly targeting stabilization and delivery tech.
- Patent strength relies on the novelty of the specific stabilizer-activator combination, with possible vulnerabilities to design-arounds.
- Commercial success depends on strategic patent management, regulatory approval, and navigating a complex international landscape.
FAQs
1. How strong are the claims in U.S. Patent 10,265,374?
They are specific but could be challenged based on prior art that discloses similar stabilization techniques or formulations.
2. Can competitors develop similar formulations without infringing?
Yes, by substituting the stabilizer or altering the formulation parameters, competitors can potentially avoid infringement.
3. What is the expiration date of this patent?
Assuming standard 20-year patent term from the filing date (2016), it expires around 2036, barring extensions.
4. Are there international equivalents to this patent?
Likely, through PCT filings or direct national filings, though specific application statuses vary by jurisdiction.
5. How does this patent influence the market?
It provides exclusivity for the claimed formulation in the U.S., potentially blocking generics in that market for the duration unless invalidated.
References
- U.S. Patent No. 10,265,374. (2019).
- Patent landscape reports on biologic formulation patents (2014-2018).
- European Patent Office database.
- PCT Application Status Reports.
- FDA Drug Approval Database.
